SPDR® S&P Biotech ETF (XBI)

BATS BZX Real-Time Price
As of 2:50pm ET
 -0.91 / -1.10%
Today’s Change
Today|||52-Week Range
XBI Regular Dividend: XBI began trading ex-dividend on 09/20/19. A $0.0032 dividend will be paid to shareholders of record as of 09/23/19.

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.


1 month+0.26% 3 years+7.14%
3 months-4.91% 5 years+9.71%
1 year-14.89% Since inception+12.91%
Data through 09/21/2019

Quote Details

Previous close$82.71
Open day’s range81.73 – 83.18
Net asset value (NAV)82.63 (09/20/2019)
Daily volume1,908,137
Average volume (3 months)4,140,313
Data as of 2:50pm ET, 09/23/2019

Peer Comparisonvs. Health ETFs

Performance 5-yr return+9.71%+9.15%
Expense Gross exp ratio0.35%1.24%
Risk 5 year sharpe ratio0.400.46
Net assets$3.9B$3.0B
Average market cap$3.4B$35.5B
Average P/E--23.4
Dividend / Share--0.26%


FHLC Fidelity MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
IHI iShares U.S. Medical Devices ETF


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
GHDX Genomic Health Inc2.22%
NVTA Invitae Corp1.87%
AMGN Amgen1.76%
NBIX Neurocrine Biosciences Inc1.76%
ALNY Alnylam Pharmaceuticals Inc1.71%
ARWR Arrowhead Pharmaceuticals Inc1.70%
MDCO Medicines Co1.69%
PTLA Portola Pharmaceuticals Inc1.67%
ACAD ACADIA Pharmaceuticals Inc1.67%
FGEN FibroGen Inc1.63%